Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
US Department of Justice
Covington
US Army
Teva
Dow
Medtronic
Mallinckrodt
AstraZeneca
Federal Trade Commission

Generated: August 17, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Abstract: The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.
Inventor(s): Ridker; Paul (Chestnut Hill, MA), Hennekens; Charles H. (Boca Raton, FL)
Assignee: The Brigham and Women's Hospital, Inc. (Boston, MA)
Application Number:11/158,889
Patent Claims: 1. A method for treating a nonhypercholesterolemic human in need thereof to reduce the risk of a cardiovascular disorder associated with atherosclerotic disease, comprising first selecting the human on the basis that the human is known to have an above-normal level of C-reactive protein and on the basis that the human is known to be nonhypercholesterolemic, and then administering to the human because the human has an above-normal level of C-reactive protein a statin lipid reducing agent in an amount effective to lower the risk of the human developing a future cardiovascular disorder associated with atherosclerotic disease.

2. The method of claim 1, wherein the subject is an apparently healthy non-smoker.

3. The method of claim 1 wherein the above-normal level of C-reactive protein is above 1.75 mg/l.

4. The method of claim 1, wherein the above-normal level of C-reactive protein is above 2.0 mg/l.

5. The method of claim 2, wherein the above-normal level of C-reactive protein is above 1.75 mg/l.

6. The method of claim 2, wherein the above-normal level of C-reactive protein is above 2.0 mg/l.

7. The method of claim 1, wherein the statin lipid reducing agent is lovastatin, fluvastatin, simvastatin, atorvastatin, pravastatin, or cerivastatin.

8. The method of claim 2, wherein the statin lipid reducing agent is lovastatin, fluvastatin, simvastatin, atorvastatin, pravastatin, or cerivastatin.

9. The method of claim 1, wherein the cardiovascular disorder associated with atherosclerotic disease is myocardial infarction.

10. The method of claim 1, wherein the cardiovascular disorder associated with atherosclerotic disease is stroke.

11. The method of claim 2, wherein the cardiovascular disorder associated with atherosclerotic disease is myocardial infarction.

12. The method of claim 2, wherein the cardiovascular disorder associated with atherosclerotic disease is stroke.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
US Department of Justice
Johnson and Johnson
Cantor Fitzgerald
Deloitte
Covington
Chinese Patent Office
Cerilliant
Citi
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot